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Abstract
Background: Targeting CTLA-4 is a recent strategic approach in cancer control: blocking CTLA-4 enhances an
antitumor immunity by promoting T-cell activation and cytotoxic T-lymphocyte proliferation. This induction of a
tolerance break against the tumor may be responsible for immune-related adverse events (irAEs). Our objective was
to assess the incidence and nature of irAEs in oncologic patients receiving anti-CTLA-4 antibodies (ipilimumab and
tremelimumab).
Methods: A systematic search of literature up to February 2014 was performed in MEDLINE, EMBASE, and Cochrane
databases to identify relevant articles. Paired reviewers independently selected articles for inclusion and extracted
data. Pooled incidence was calculated using R©, package meta.
Results: Overall, 81 articles were included in the study, with a total of 1265 patients from 22 clinical trials included
in the meta-analysis. Described irAEs consisted of skin lesions (rash, pruritus, and vitiligo), colitis, and less frequently
hepatitis, hypophysitis, thyroiditis, and some rare events such as sarcoidosis, uveitis, Guillain-Barré syndrome,
immune-mediated cytopenia and polymyalgia rheumatic/Horton. The overall incidence of all-grade irAEs was 72 %
(95 % CI, 65–79 %). The overall incidence of high-grade irAEs was 24 % (95 % CI, 18–30 %). The risk of developing
irAEs was dependent of dosage, with incidence of all-grade irAEs being evaluated to 61 % (95 % CI, 56–66 %) for
ipilimumab 3 mg/kg and 79 % (95 % CI, 69–89 %) for ipilimumab 10 mg/kg. Death due to irAEs occurred in 0.86 %
of patients.
The median time of onset of irAEs was about 10 weeks (IQR, 6–12) after the onset of treatment, corresponding with
the first three cycles but varied according to the organ system involved. Such immune activation could also be
indicative for tumor-specific T-cell activation and irAE occurrence was associated with clinical response to CTLA-4
blocking in 60 % of patients.
Conclusion: The price of potential long-term survival to metastatic tumors is an atypical immune toxicity, reflecting
the mechanism of action of anti-CTLA-4 antibodies. A better knowledge of these irAEs and its management in a
multidisciplinary approach will help to reduce morbidity and therapy interruptions.
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Background
Approval of the first cancer immunotherapies suggests a
promising therapeutic approach in some metastatic can-
cers [1]. In contrast to most oncologic treatments, anti-
bodies target lymphocyte receptors or their ligands (and
not the tumor cells directly) in order to enhance en-
dogenous anti-tumor activity. Among these receptors,
cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4)
is a particularly important immune checkpoint receptor
and the first to be clinically targeted in oncology.
The concept of immunosurveillance and involvement
of the immune system in cancer development has been
known for several years [2]. In the last two decades, ef-
forts to activate anti-cancer host immunity were focused
on T-cells due to their central role in the anti-cancer
adaptive immune response, which is regulated by numer-
ous co-stimulatory and inhibitory signals through tumor
antigen recognition by the T-cell receptor. Thus, block-
ades of immune checkpoints with antagonists of inhibitory
pathways have been developed and anti-CTLA-4 anti-
bodies are precursors in this domain [3] (Mechanism of
action: anti CTLA-4 antibodies in Fig. 1). CTLA-4,
expressed exclusively on T-cells, acts as a negative co-
stimulatory signal, inhibiting T-cell activation and pro-
liferation to maintain self-tolerance and protect from
autoimmunity [4]. This role is supported by the lethal
lympho-proliferation and autoimmunity in CTLA-4 knock-
out mice [5]. Recently, heterozygous germline mutations in
CTLA-4 have been identified in four unrelated families
with severe immune dysregulation [6]. Interestingly, these
mutations show the spectrum of clinical immune complica-
tions that can be anticipated from anti-CTLA-4 drugs.
Thus, a fully humanized anti-CTLA-4 monoclonal
antibody immunoglobulin (Ig) G1 isotype (ipilimumab)
was approved by the Food and Drug Administration
(FDA) in 2011 at a dosage of 3 mg/kg every 3 weeks for
four cycles in advanced melanoma, with evidence of im-
proved survival [7, 8]. An IgG2 isotype (tremelimumab)
was developed at a dosage of 15 mg/kg every 90 days to
minimize complement activation and reduce the risk of
cytokine release syndrome [9]. The clinical value of anti-
CTLA-4 antibodies is being investigated in various cancer
types including prostate, renal, bladder, colorectal, esopha-
geal, pancreatic, gastric, hepatocellular, and pulmonary
malignancies as well as mesothelioma and lymphoma [10].
As might be expected with blocking CTLA-4, the induc-
tion of a tolerance break against the tumor may be respon-
sible for a variety of specific immune-related adverse events
(irAEs) that occur in approximately 60 % of the patients
treated by ipilimumab [7]. These include skin, gastrointes-
tinal, hepatic, endocrine, neurologic, hematologic, ophthal-
mologic, and rheumatologic autoimmune diseases.
Our objective was to assess the incidence and the na-
ture of irAEs in oncologic treatment with anti-CTLA-4
antibodies (ipilimumab and tremelimumab) through a
systematic review and meta-analysis of the literature.
Methods
Data sources and searches
A systematic literature search was performed up to
February 2014 in the Medline, Embase, and Cochrane
databases to identify relevant articles. Two investigators
(AB and MK) together determined the optimal search
strategy checking several combinations of keywords with
Fig. 1 Mechanism of action: CTLA-4 and anti-CTLA-4 antibodies. Two signals are required to initiate an immune response. For the first signal
(signal 1), tumor associated antigen (Ag), is presented by major histocompatibility complex (MHC) on antigen presenting cell (APC) and recognized by
the toll-like receptor (TCR) of T-cell. Signal 2 occurs in response to binding of CD80 or CD86 (B7) on APC cell with CD28 receptor on T-cell (a). CTLA-4 is
a homolog of CD28 and limits proliferative response of activated T-cell competing with CD28 for ligand B7. This inhibition occurs in response to
binding of CD80 or CD86 on APC with CTLA-4 receptor on T-cell and interrupts signal 2 (b). Anti-CTLA-4 antibodies blocks CTLA-4 and enhances T-cell
activation and proliferation (c)
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the Boolean logical operators AND/OR. A consensus
was reached and validated by all authors. Hence, the
keywords used were “safety OR security OR side effects
OR adverse events AND (anti CTLA4 OR anti CTLA-4
OR ipilimumab OR tremelimumab)” in Medline and
Embase, and “anti CTLA4 OR anti CTLA-4 OR ipilimu-
mab OR tremelimumab” in the Cochrane database. The
search was limited to studies on human beings and pub-
lished in English. Manual searches from bibliographic
references were also performed after reading of the first
selection of articles. Articles published as full text were
preferable in order to study irAEs in detail and to check
the quality assessment of trials included in the meta-
analysis. Additionally, many medical specialties are con-
cerned with these side effects due to their diversity and
it would thus be difficult to check all conference meet-
ings in 2 years prior to the study. Therefore, unpublished
studies were not searched.
Eligibility criteria and study selection
We included clinical trials and case reports that reported
irAEs in oncologic patients receiving anti-CTLA-4 anti-
bodies (ipilimumab or tremelimumab). Patients included
were adults with a diagnosis of metastatic cancer or unre-
sectable tumor. They could have received previous onco-
logic therapy before inclusion. Patients with anti-CTLA-4
prescribed in combination with other treatments or pa-
tients with previous receipt of anti-CTLA-4 antibodies
were excluded. The two investigators conducted study se-
lection and manual searches in bibliographic references
independently, selecting the relevant articles initially on
the basis of titles and abstracts, and then on the full texts.
Outcomes
Incidence evaluation was based on the number of irAEs
for global and specific irAEs (skin, gastrointestinal,
endocrine, and hepatic diseases) and their grade (1–5;
recorded according to Version 2, 3 or 4 of the Common
Terminology Criteria for Adverse Events of the National
Cancer Institute). Grades ≥3 were considered high-grade.
Data extraction
Each investigator performed the reading and data extrac-
tion independently. They used, for each study, a stand-
ard data extraction form and re-read together the
articles in the event of any discrepancy in their interpret-
ation. When data were not available, efforts were made
to contact first authors.
Clinical trials were used to determine the incidence
of irAEs. Information on the author and year of publi-
cation, population size, study design, treatment (ipili-
mumab or tremelimumab) and dosing regimen,
duration of treatment (and number of infusions), and
irAEs outcomes was extracted.
Case reports were used to describe the diversity of
irAEs. Patient characteristics, the previous oncologic
treatment, and the nature of each irAE, their onset, their
treatment, and outcome were all recorded. Cancer out-
come was also noted when reported in the article
(partial or complete remission, stability, or progression).
Quality assessment
The Cochrane Collaboration’s tool was used to assess
risk of bias and to evaluate the quality of articles in-
cluded in the meta-analysis [11], addressing sequence
generation, allocation concealment, blinding of partici-
pants and personnel, incomplete outcome data, selective
outcome reporting, and other sources of bias. Disagree-
ments among investigators were discussed and agree-
ment was reached by consensus.
Data synthesis and analysis
The primary objective of the study was the number of
irAEs for each group of treatment (ipilimumab and tre-
melimumab). An incidence was estimated for each study
included in the meta-analysis estimation. Statistical het-
erogeneity among the selected studies was tested based
on the Q-test (χ2), using a significant level of 0.05, and
reported with the I2 statistic in which high values indi-
cate high heterogeneity. If heterogeneity was not
rejected by the Q-test or under a threshold of 30 %, all
meta-analyses were carried out using the inverse vari-
ance approach (fixed-effect model); otherwise, the in-
verse variance corrected by the inter-study variability
was used (random-effect model). This method was not
relevant for the question addressed herein due to the
presence of zero values in adverse event incidences. In
this case, a correction (λ) was introduced in the variance
calculation (classically adding 0.5 to the number of event
counts), and the exact formula of variance became:
count þ λð Þ n−count þ λð Þ
nþ 2λð Þ3
It provided a common weighted incidence estimate
with 95 % confidence interval (CI), taking into account
the weight of the different samples. Incidences and their
95 % CIs were shown on forest plots. Publication bias
was assessed using the funnel plot method. All compu-
tations were performed using R software (R version




The literature search identified 491 articles in databases
and manual searches retrieved five additional articles.
Among these 496 articles, 373 were excluded after
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reading of the abstracts due to duplicate articles, oncologic
treatment in combination with other drugs, review arti-
cles, or basic research. Finally, 123 articles were fully
reviewed and 81 were considered relevant for the present
study: 24 clinical trials and 57 case reports (Fig. 2).
Clinical trials in which patients were treated according
to the labeling of the products (ipilimumab 3 mg/kg
every 3 weeks for at least four cycles and tremelimumab
at 15 mg/kg every 90 days) or at upper dosage were in-
cluded for meta-analysis. As one study was retrospective
and one used ipilimumab for only one or two doses,
these two studies were only selected in the systematic
review but not for meta-analysis [12, 13].
Incidence of irAEs – data from clinical trials
General characteristics
In total, 1265 patients from 22 clinical trials were included
for meta-analysis to assess the incidence of irAEs with
anti-CTLA-4 treatment (Table 1) [7, 14–34]; 18 studies
concerned ipilimumab treatment and four concerned tre-
melimumab, but incidence data of global irAEs for treme-
limumab was available in only one study [31]. Moreover,
the tremelimumab phase III randomized clinical trial in
advanced melanoma was not included because 46 patients
(14 %) received ipilimumab in the control arm [35]. Most
of the studies were not blind (18/22). Single arm studies
were retrieved in 11 articles, six studies were randomized
and five were not. Half of the studies were monocentric.
Anti-CTLA-4 antibodies were mainly given for mela-
nomas. Other studies concerned renal cell carcinoma,
mesothelioma and pancreatic, gastric, esophageal, colo-
rectal, prostatic, and bladder cancer. The median dur-
ation of follow-up in these clinical trials was 23 months
(IQR, 19–32). It is noteworthy to consider that, in 20
studies (90 %), patients with pre-existing autoimmune
disease were not eligible for inclusion.
Global incidence of irAEs
The overall incidence level of irAEs reported with anti-
CTLA-4 treatment was 72 % (95 % CI, 65–79; I2, 81.94)
for all-grade and 24 % (95 % CI, 18–30; I2, 79.97) for
high-grade (Fig. 3a,b).
The incidence of all-grade irAEs varied according to
the dosage of the drug, from 61 % (95 % CI, 56–66; I2,
0) in patients receiving ipilimumab at 3 mg/kg to 79 %
(95 % CI, 69–89; I2, 85) in patients treated with ipilimu-
mab 10 mg/kg. This dose effect was corroborated in
high-grade irAEs, evaluated to 17 % (95 % CI, 10–23; I2,
71, 85) with ipilimumab 3 mg/kg and 31 % (95 % CI,
22–39; I2, 62) with ipilimumab 10 mg/kg (Figures S5, S6
and S7 in Additional file 1). To perform a statistical
comparison between the two main doses (3 mg/kg and
10 mg/kg) we made a subgroup analysis within the three
studies comparing the two doses [17, 19, 30]. The risk
ratio (RR) of developing an irAE with ipilimumab at 10
mg/kg compared with 3 mg/kg was 3.10 (1.59–6.03;
Fig. 2 Flow diagram for identification and selection of studies included in the systematic review and meta-analysis
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P=0.0008) for the overall incidence level of irAEs for
high grade. RR of overall incidence level of irAEs for all
grade did not reach a statistically significant difference
(RR, 1.16 (0.97–1.38); P=0.10; Fig. 4a,b).
Incidence of organ-specific irAEs
The skin and the gastrointestinal tract were mostly af-
fected, in 44 % (95 % CI, 38–49.5) and 35 % (95 % CI,
29–41) of cases, respectively, while endocrine and hep-
atic organs were less affected, in 6 % (95 % CI, 4–8) and
5 % (95 % CI, 2–7), respectively. Other events, such as
neurologic, hematologic, ophthalmologic, or rheumato-
logic diseases, were rare.
Almost all skin, endocrine, and hepatic irAEs were low
grade (less than 5 %); high-grade irAEs remained more fre-
quent in gastrointestinal events at 11 % (95 % CI, 8–13.5;
Fig. 3c and Figure S8 to Figure S27 in Additional file 1).
As global irAEs, organ-specific irAEs seemed to be
more important for patients treated with ipilimumab at
10 mg/kg except for high-grade endocrine irAEs (Fig. 3c).
However, in the subgroup analysis [17, 19, 30], a statisti-
cally significant difference was only found between the
two doses for all grade gastrointestinal irAEs with a RR
of 1.43 (1.04–1.96; P=0.03; Figures S28 to S31 in
Additional file 1).
There appeared to be fewer irAEs with tremelimumab,
except those concerning hepatic disease.
Incidence of death related to irAEs
Death due to irAEs occurred in 11 patients (0.86 %),
often related to colic bowel perforation for patients
with colitis.
Nature of irAEs – data from case reports and
retrospective studies
General characteristics
In addition to retrospective studies and some descriptive
clinical trials, our research identified 100 patients from
Table 1 Characteristics of studies included for meta-analysis
Trial Design Cancer Enrollment size Anti-CTLA-4 Dose (mg/kg) CTC for AE version
Hodi [7] RCT, phase III Melanoma 676 Ipilimumab 3 3
Wilgenhof [14] Prospective observational study Melanoma 50 Ipilimumab 3 4
Delyon [15] Prospective observational study Melanoma 96 Ipilimumab 3 4
Margolin [16] Open label, phase II Melanoma 72 Ipilimumab 10 3
Hamid [17] Randomized, double blind,
phase II
Melanoma 82 Ipilimumab 3; 10 n/a
Danielli [18] Single arm, phase II Melanoma 13 Ipilimumab 10 3
Wolchok [19] Randomised phase II,
dose ranging study
Melanoma 217 Ipilimumab 0.3; 3; 10 3
O’Day [20] Multicenter, single arm, phase II Melanoma 155 Ipilimumab 10 3
Hersh [21] RCT, phase II Melanoma 74 Ipilimumab 3 2
Weber [22] Randomized, double blind,
phase II
Melanoma 115 Ipilimumab 10 3
Yang [23] Randomized, double blind,
phase II, dose ranging study
Renal cell 61 Ipilimumab 1; 3 n/a
Downey [24] Multicenter, single arm, phase II Melanoma 139 Ipilimumab 9 n/a
Ku [25] Compassionate use trial Melanoma 53 Ipilimumab 10 3
Di Giacomo [26] Single arm, phase II Melanoma 27 Ipilimumab 10 3
Royal [27] Single arm, phase II Pancreatic 27 Ipilimumab 3 3
Le DT [28] Randomized, open label,
phase IB
Pancreatic 30 Ipilimumab 10 3
Weber [29] Phase I/II Melanoma 88 Ipilimumab n/a n/a
Slovin [30] Non randomized, open label,
multicenter, phase I/II
Prostate 71 Ipilimumab 3; 5; 10 3
Calabro [31] Open label, single arm, phase II Mesothelioma 29 Tremelimumab 15 3
Chung [32] Multicenter, single arm, phase II Colorectal 47 Tremelimumab 15 3
Ralph [33] Single arm, phase II Gastric and esophageal 18 Tremelimumab 15 2
Ribas [34] Phase I Melanoma, renal cell, colon 39 Tremelimumab 10; 15 2
CTC for AE version, Common Terminology Criteria for Adverse Events version; RCT, Research clinical trial; n/a, Non-available
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Fig. 3 Incidence of global immune-related adverse events (irAEs) with anti-CTLA-4, all-grade (a) and severe grade (b). For ipilimumab treatment,
different dosages were used: 3 mg/kg, 10 mg/kg, and 15 mg/kg. Only one study [31] reported global irAEs with tremelimumab treatment, at 15
mg/kg dosage. IrAEs associated with anti-CTAL-4 antibodies (c)
Fig. 4 Risk ratio of developing an irAE with ipilimumab at 10 mg/kg compared with 3 mg/kg for global irAEs all grade (a) and high grade (b)
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57 case reports with at least one irAE [26, 36–91].
Among them, 18 presented several irAEs. The general
characteristics of these patients are summarized in
Additional file 1: Table S2. Anti-CTLA-4 treatments
were mainly used in melanoma (94 %). Ninety-nine pa-
tients received ipilimumab and one patient received tre-
melimumab; 48 patients (48 %) had failed at least one
previous oncologic therapy before receiving anti-CTLA-
4 antibodies. The irAEs occurred in a median of 10
weeks (IQR, 6–12), within the first three cycles of ipili-
mumab treatment.
Interestingly, clinical remission (partial or complete),
or at least cancer stabilization, was noted for 60 % of pa-
tients who experienced an irAE. When irAEs were diag-
nosed, anti-CTLA-4 was stopped in 76.2 % of patients.
Nature of irAEs
Cutaneous irAEs were by far the most common immune
side effect of anti-CTLA-4 treatment and occurred within
the first month of treatment. Pink red papules coalescing
into thin plaques associated with mild to severe pruritus
were usually described. A Koebner phenomenon was
sometimes associated. This dermatitis was usually well tol-
erated and limited. It was mainly localized at proximal ex-
tensor surfaces of the limbs, trunk, and distal extremities.
Palms and soles were often spared and head involvement
was rare [92].
Histologically, an epidermal spongiosis and a superficial
perivascular CD4 predominant T-cell infiltrate were
present. An increased tissue (in papillary dermis) and per-
ipheral blood eosinophil levels were described [93]. Treat-
ment consisted of topical corticosteroids. Severe grades
were treated with oral corticosteroids (starting at 1 mg/kg)
and discontinuation of anti-CTLA-4 treatment.
Exacerbation of pre-existing dermatitis as eczema, viti-
ligo, or rosacea and extensive alopecia were also reported
[36, 37, 92]. Moreover, a case of Sweet’s syndrome was re-
ported in a patient undergoing ipilimumab therapy for
metastatic melanoma [38]. After the second infusion, she
developed fever and cutaneous eruption on her hands.
Punch biopsy confirmed neutrophilic dermatitis and
symptoms improved with corticosteroids therapy.
Endocrine irAEs were part of this spectrum of specific
irAEs reported to anti-CTA-4 antibodies (Additional file 1:
Table S3). They occurred within an average of 11 weeks but
were not dose dependent, unlike other irAEs.
Autoimmune hypophysitis was the most frequent
endocrine side effect, reported in up to 13 % of clinical
trials. It was similar to lymphocytic hypophysitis, sharing
the same clinical, biological, and radiological features
[94]; 33 cases were reported. Symptoms were related to
the anterior hypopituitarism (hormonal deficiencies) and
pituitary mass effect [39]. Most patients presented head-
ache (51.8 %: 14/27 patients), asthenia (59.3 %: 16/27),
erectile dysfunction, and decreased libido. Visual dis-
turbances were rare, reported only in one patient [40].
Indeed, mass syndrome was usually moderate: 3.4–6
mm in pre-treatment and 7.7–11.8 mm after ipilimu-
mab therapy [39]. Affected areas were mainly the
hypothalamic-pituitary-adrenal axis (92.9 %; 26/28 pa-
tients) and the thyrotropin axis (89.3 %; 25/28),
followed by the gonadal axis (71.4 %; 20/28). The lacto-
trope and somatotropic axes were less frequently in-
volved (21.4 % (6/28) and 10.7 % (3/28), respectively).
One case of hypernatremia secondary to syndrome of
inappropriate antidiuretic hormone and one case of
diabetes insipidus were associated with ipilimumab-
induced hypophysitis [41, 42]. MRI aided in the diag-
nosis of hypophysitis by identifying enlargements of
the pituitary gland (68.2 %; 15/22) and homogeneous
enhancements after injection of gadolinium (31.8 %;
7/22); MRI could be normal (6/22), without excluding
the diagnosis. Treatment consisted of hormone substi-
tution and high-dose oral corticosteroids with a
median dose of 80 mg prednisone equivalent (IQR,
60–106), decreasing over 1 month and backed by
hydrocortisone. MRIs normalized with corticosteroids
in six patients. However, hormonal deficits persisted
in 75 % (15/20) and required long-term hormonal re-
placement, especially corticosteroids. Five cases re-
ported complete healing.
Hypo- and hyperthyroidism secondary to thyroiditis
were rare, up to 5.6 % in clinical trials. One case re-
ported bilateral Graves’ ophtalmopathy with high thyro-
peroxydase and thyroglobulin antibodies after two cycles
of ipilimumab therapy [43].
Gastrointestinal irAEs were important and potentially
severe immune complications reported with CTLA-4
blocking drugs (Additional file 1: Table S3). Patients re-
ceived an average of three infusions (IQR, 2–4) before
the onset of symptoms.
Colitis was reported in 21 patients. Clinical manifesta-
tions were diarrhea (95.2 %; 20/21), abdominal pain (38.1
%; 8/21), rectal blood (23.8 %; 5/21), and nausea, with or
without fever. Colitis could be life threatening with fatal
colic bowel perforation, reported in two patients [54].
Colonoscopy could be normal or reveal variable abnor-
malities, including edema, erythema, ulcers, friability, ex-
udate, erosions, or bleeding [55].
Histology showed ulcerative epithelial defect (35.3 %;
6/17), lymphocytic (64.7 %; 11/17) or neutrophilic infil-
trates (52.9 %; 9/17), or both (35.3 %; 6/17), and some-
times with eosinophil cells. Crypt micro-abscesses and
architectural distortion were also occasionally seen [55].
Histopathology shared some features with inflammatory
bowel disease and graft versus host disease. Colitis man-
agement is proposed in analogy with the treatment of
these two pathologies [95].
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Treatment consisted of symptomatic drugs (loperamide)
and rehydration for grade 1 irAEs. For grade 2, anti-
CTLA-4 discontinuation and moderate dose of oral ste-
roids or budesonide are recommended. For severe grades,
a high dose of steroids (sometimes intravenous) was rec-
ommended as first line treatment. In case reports, the
median dose was 156 mg prednisone equivalent (IQR,
150–225) and in the event of no improvement in 1 week,
infliximab (one or two infusions at 5 mg/kg) was pro-
posed. For refractory colitis, a colectomy had to be per-
formed [57]. Healing was reported in 91.5 % of patients.
Hepatitis was described in up to 19 % of clinical trials.
Patients presented elevated alanine aminotransferase and
aspartate aminotransferase, with or without hyperbilirubi-
nemia, usually in the absence of clinical symptoms [63]. Bi-
opsies from patients experiencing acute immune-related
hepatotoxicity showed T-cell infiltrates (87.5 %; 7/8). Most
patients responded to corticosteroids but several cases
needed immunosuppressive therapies such as tacrolimus,
mycophenolate, or antithymocyte globulin therapy [63, 64].
One case illustrated ipilimumab-related pancreatitis
considered to be immune-related due to detection of
anti-pancreas antibodies [66].
A case of coeliac disease was also reported [67]. Biology
revealed anti-tissue transglutaminase and anti-gliadine
antibodies. The duodenal biopsies showed a malabsorptive
pattern; a gluten-free diet helped to stop diarrhea.
Other irAEs
Various neurologic irAEs, such as Guillain-Barré syn-
drome [42, 68, 69], transverse myelitis [70], aseptic menin-
gitis [42], inflammatory myopathy [71], orbital myositis
[72], or myasthenia [70], were described (Additional file 1:
Table S3). Despite adapted treatments (steroids, immuno-
globulin therapy, and plamapheresis), authors reported
three deaths and five patients with long-lasting neurologic
irAEs related to anti-CTLA-4.
Additionally, six cases of sarcoidosis were reported
[77–82]. Symptoms occurred in the first four cycles
(IQR, 3–5) corresponding within the first 15 weeks
(IQR, 12–24). Dyspnea (50 %; 3/6) and skin lesions (50 %;
3/6) were usually described. Computed tomography
showed mediastinal lymph nodes in 83.3 % (5/6) of cases
and micronodular and reticulonodular lesions in 80 % (4/
6). Diagnosis was confirmed by biopsies (bronchial or cu-
taneous) revealing granulomas in all (5/5) cases. Healing
was reported in all cases with oral steroids treatment at a
dosage of 75 mg prednisone equivalent (IQR, 50–100).
Many other events were also reported with anti-CTLA-
4 antibodies, including uveitis [83], organizing pneumonia
[84], lupus nephritis [85], autoimmune cytopenia [85–87],
and hemophilia A [89], as well as a recently published case
of polymyalgia/giant cell arteritis [90].
Quality assessment
Most of the studies were not blind or single-arm since the
majority were compassionate trials. Thus, since investiga-
tors were aware of which treatment patients had received
and of the possible drug side effects, it is possible that
irAEs were over-reported. Despite these elements, most
information was retrieved from trials with a moderate risk
of bias. Further details regarding the quality assessment
are available in Additional file 1: Table S4. No significant
publication bias was found for all meta-analysis.
Discussion
To our knowledge, this is the first systematic review and
meta-analysis reporting overall published irAEs related
to anti-CTLA-4. From 22 clinical trials included in the
pooled analysis, we found a respective incidence of 72 %
(95 % CI, 65–79; I2, 81.94) for all-grade irAEs and 24 %
(95 % CI, 18–30; I2, 79.97) for high-grade irAEs leading
to hospitalization or intravenous treatment. These re-
sults highlight the high risk of irAEs with anti-CTLA-4
drugs in patients with such metastatic cancers. These
values were found to be quite similar to those of a retro-
spective review of safety data including 1498 patients
treated with ipilimumab at various doses on 14 com-
pleted phase I–III trials [96], reporting inflammation
drug-related adverse events in 64 %, with 18 % being of
severe grades.
Among the wide spectrum of irAEs, cutaneous reactions
and gastrointestinal tract immune side effects were com-
monly encountered, followed by endocrinopathies and
hepatitis. However, several reports included nervous sys-
tem disorders, sarcoidosis, respiratory, renal, or other
organ immune involvement. Indeed, physicians of various
specialties should be concerned by these irAEs and must
examine all symptoms as being potentially induced by
anti-CTLA-4 treatment. Voskens et al. [97] summarized
and described, by organ system, the rare ipilimumab-
induced immune side effects among 19 skin cancer
centers. Through this complete description of previously
unreported irAEs, several specialized centers shared their
experience of irAEs in order to increase awareness and
introduce an earlier management of potentially severe side
effects. Recently, Teply et al. [98] also provided identifica-
tion, description, and management of toxicities from
immune checkpoint-blocking drugs (CTLA-4, PD-1, and
PD-L1 antibodies).
An important clinical point is the early onset of irAEs,
in general within the first 10 weeks, corresponding to a
mean of three cycles for ipilimumab treatment, but var-
ies according to the organ system involved. McDermott
et al. [99] reported the occurrence of new ipilimumab-
related immune toxicity in 7 of 78 patients with 2 years’
survival after ipilimumab treatment. These irAEs were
mostly low grade and occurred more than 70 days after
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the last dose of ipilimumab. Three studies provide add-
itional information on the safety profile of ipilimumab
retreatment, comparable with that observed during ipili-
mumab induction and without new types of toxicity
[100–102]. Lebbé et al. [100] observed a lower incidence
of irAEs among patients retreated with ipilimumab 10
mg/kg who were previously treated with ipilimumab 3
mg/kg (67.6 %) and 10 mg/kg (56.6 %) compared with
patients who received ipilimumab 0.3 mg/kg (75 %); this
was also reported by Chiarion-Sileni et al. [101] in the Ital-
ian expanded program. They suggested the possibility of a
dose-dependent CTLA-4 binding in caution with the se-
lection bias since patients with high-grade irAEs in the
parent study would not have been eligible for retreatment.
Few data are published on the long-term follow-up of
anti-CTLA-4-induced irAEs. Indeed, anti-CTLA-4 anti-
bodies are a recent approach in oncology and the
follow-up in clinical trials is currently too short to assess
long-term evolution of these side effects. Based on case
reports, 91.5 % of patients experiencing a gastrointes-
tinal (colitis) irAE and 100 % of patients with sarcoidosis
recovered completely of their irAEs. However, patients
with endocrine side effects (hypophysitis) were reported
as healed in only 25 % of cases. This data is relevant
with a recent study following up anti-CTLA-4-induced
hypophysitis for over 2.5 years and reporting a long-
term hormonal replacement requirement in 86.6 % of
patients [103]. Indeed, the clinical features, management,
and evolution of irAEs seem to be similar to known
autoimmune diseases. These similarities beg the follow-
ing questions: Do patients developing irAEs have par-
ticular genetic risk factors (e.g. HLA-DR alleles) such as
those in autoimmune diseases? Could the CTLA-4
blockade be the trigger of long-term auto-immunity?
Further studies are needed to provide these answers.
The overall incidence of irAEs observed with the two
main doses of ipilimumab (3 mg/kg and 10 mg/kg) seem
to be significantly different and have a dose-dependent
effect since the CIs of means did not overlap. The sub-
group analysis confirmed this hypothesis, with a RR at
3.10 (1.59–6.03; P=0.0008) of developing irAEs with a
higher dosage (10 mg/kg) for high-grade global irAEs. It
seems that treatment with tremelimumab has less irAEs,
but the mechanism remains unclear. Patients receiving a
lower dosage of FDA-approved therapy were not in-
cluded in this meta-analysis, but it is noteworthy that
there were very few irAEs for these sub-therapeutic
doses [13].
Efficacy is also reported as having a dose-dependent
effect [19]. A major question is the existence of a rela-
tionship between oncologic response and occurrence of
irAEs, which could be indicative of tumor-specific T-cell
activation. The present study has not been established to
answer this question. However, based on case reports,
irAE occurrence seems to be associated with clinical re-
sponse to CTLA-4 blocking: 60 % of the patients pre-
senting with irAEs experienced clinical remission (partial
or complete) or at least cancer stabilization. Interest-
ingly, several studies have also reported a strong correl-
ation between clinical response to anti-CTLA-4 therapy
and irAEs [23, 24, 95, 104, 105]. Thus, objective tumor
response rates were around 30 % in patients who devel-
oped autoimmune events, while 0–10 % of the other pa-
tients responded to treatment. In a study by Downey et
al. [24], all complete responders experienced high-grade
irAEs. These observations corroborate the idea of a
coupling autoimmunity and tumor immunity.
Under normal physiological conditions, CTLA-4 acts as
a negative T-cell co-stimulatory signal, maintaining the
peripheral T-cell homeostasis and tolerance to self or en-
vironmental antigens [106]. Expression on activated con-
ventional T-cells is induced after T-cell receptor signaling
(Fig. 1) while it is constitutively expressed on T-regulator
cells (CD4+FoxP3+). CTLA-4 is now established as a crit-
ical regulator of T-regulator homeostasis and function
[107]. Thus, if the CTLA-4 blockade enhances the intratu-
moral T-effector/T-regulator cell ratio in cancer patients,
by depleting T-regulator cells [108], immunotherapy
modulating CTLA-4 (such as abatacept) improves the
regulatory T-cell inhibitory function in rheumatoid arth-
ritis patients [109]. This example highlights the opposite
therapeutic strategy between cancer patients and those af-
fected by inflammatory/autoimmune diseases. Further-
more, T-regulator cell differentiation in the gut by
commensal bacteria is known to actively engender muco-
sal tolerance. The frequency of colitis in patients receiving
CTLA-4 blockade could be explained, in part, by the T-
regulator depletion induced by this treatment [110].
Thus, given the critical role of CTLA-4 in immunologic
homeostasis and the known irAE profile, patients with
underlying autoimmune disease were usually excluded
from clinical trials involving CTLA-4 blocking drugs. Few
reports have been published concerning patients treated
with ipilimumab despite an active autoimmune disease as
rheumatoid arthritis, multiple sclerosis, ulcerative colitis,
or Behçet’s disease [111, 112]. In three patients who pre-
sented rheumatoid arthritis, ulcerative colitis, and Behçet’s
disease, no aggravation of the immune disorder was noted
and their cancer benefitted from the treatment. Although
anecdotal, these descriptions raise the question of the
current exclusion of anti-CTLA-4 treatment in patients
with autoimmune disease, given the poor prognosis of a
metastatic cancer. Furthermore, Lipson et al. [113] re-
ported two successful administrations of ipilimumab to
patients receiving an immunosuppressive regimen for kid-
ney transplantation. It illustrates that ipilimumab could be
a safe and effective option for solid organ transplantation
in patients with a higher risk of melanoma.
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The management of immune toxicities has been well-
developed by the manufacturer by working with the
FDA to edit and diffuse irAE management guidelines
[114]. In parallel, experts detailed and considered the
management of irAEs by organ system [98, 115, 116].
Patients usually required high-doses of corticosteroids
according to the irAE type and grade. Of note, a prophy-
lactic strategy with budesonide to prevent ipilimumab-
induced colitis was ineffective, with a similar rate of
diarrhea/colitis for patients receiving budesonide and
those receiving placebo [22]. Another important clinical
finding is the lack of evidence that steroid administra-
tion affects oncologic response [95, 104]; immunosup-
pressive agents were used in the event of no early
improvement (e.g. infliximab in colitis).
Ongoing research focuses on the identification of pre-
dictive biomarkers of treatment response and of irAE oc-
currence. A limited proportion of patients receiving
CTLA-4-blocking drugs achieve the objective tumor re-
sponse, while most have irAEs. Individual data from
these long-term survivors will help identify genetic and/
or immunological biomarkers in order to define patient
subsets likely to benefit from immunotherapy with ad-
equate immune monitoring. Preliminary studies have in-
vestigated the genetic variation in CTLA-4; some
variants seem to influence the response to therapy with
improved overall survival and no occurrence of irAEs
[117, 118]. Snyder et al. [119] also defined a genetic basis
for benefit from CTLA-4 blockade in melanoma by
whole-exome sequencing on tumors and matched blood
samples. They identified a neo-antigen landscape specif-
ically present in tumors with a strong response to
CTLA-4. Regarding immunological parameters, a signifi-
cant increase in T-cell ICOS expression (costimulatory
molecule, third member of the CD28/CTLA-4 family)
following ipilimumab treatment was found in melanoma
patients who experienced disease control [120]. Recently,
Vudattu et al. [121] described a reconstituted “human-
ized” mice model of human autoimmune disease in vivo
that may provide insights into anti-CTLA-4 antibody ef-
fects on autoimmunity. These “humanized” mice treated
with anti-CTLA-4 antibodies develop hepatitis, adrenali-
tis, and sialitis, as well as anti-nuclear antibodies (IgM
or IgG). Thus, this model could be relevant to describe
the irAEs observed in humans treated with anti-CTLA-4
antibodies and explore the immunologic pathways of
these side effects [121].
Our study has some limitations. First, the diagnosis of
irAEs may vary among investigators as definitions of
irAEs in clinical trials are unclear. In Hodi et al. [7], an
irAE was defined as an adverse event that was associated
with exposure to the study drug and that was consistent
with an immune phenomenon. For example, a rash
could be a dermatologic irAE or an allergic reaction, and
unfortunately we do not know if all patients with a rash
were given a biopsy. This may lead to an overestimation
of the incidence of irAEs associated with anti-CTLA-4.
However, when the immune characteristic of the drug-
related adverse event was not specified, we did not rec-
ord it. It would have been better to present results with
an odds ratio to evaluate a risk, but this was not possible
because most oncologic studies are single arm or com-
pared with a chemotherapy gold standard, not a placebo.
We selected patients receiving anti-CTLA-4 antibodies
alone, and not in combination treatment, in order to esti-
mate the real incidence of irAEs induced by these mole-
cules. Most studies and reports concerned ipilimumab
treatment due to the marketing authorization in advanced
melanoma and future data concerning tremelimumab and
other immunotherapies will be interesting. Finally, high
level of heterogeneity was observed in this meta-analysis
(around 80 % for the majority of calculations). This het-
erogeneity was taken into account by performing random
effects models, and its principal source was certainly the
heterogeneity of the studies analyzed (differences in pa-
tient’s profiles, various dosages of treatments, etc.).
Given the “up-to-date” subject and the emergence of
cancer immunotherapy, increasing reports of anti-
CTLA-4-induced irAEs are published. Indeed, since our
deadline of literature search, various auto-immune
hematological [122, 123], renal [124], cutaneous [125–128],
ophthalmologic [129–132], neurologic [133, 134], endo-
crine [132, 135–137], gastrointestinal [138, 139], and a
central nervous system sarcoidosis [140] cases have
been described.
Conclusion
The potential price of a long-term cure of metastatic tu-
mors is atypical immune toxicity, reflecting the immune
mechanism of action of anti-CTLA-4 antibodies. A better
knowledge of these irAEs and their management in a
multidisciplinary approach will help to reduce morbidity
and to guide therapy interruptions. Further studies are re-
quired to identify specific patient characteristics and/or
biomarkers that may be associated with ipilimumab clinical
efficacy in patients who did and did not develop an irAE.
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